Handelsbanken Fonder AB increased its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 27.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,302 shares of the biotechnology company's stock after acquiring an additional 9,400 shares during the quarter. Handelsbanken Fonder AB owned about 0.06% of Axon Enterprise worth $17,303,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of AXON. Dorsey Wright & Associates increased its stake in shares of Axon Enterprise by 0.3% in the second quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company's stock worth $4,135,000 after purchasing an additional 39 shares during the period. Avantax Advisory Services Inc. lifted its holdings in shares of Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company's stock worth $1,659,000 after buying an additional 40 shares during the last quarter. Brookstone Capital Management boosted its position in shares of Axon Enterprise by 5.1% in the first quarter. Brookstone Capital Management now owns 839 shares of the biotechnology company's stock valued at $263,000 after acquiring an additional 41 shares during the period. CWM LLC boosted its position in shares of Axon Enterprise by 1.5% in the second quarter. CWM LLC now owns 2,820 shares of the biotechnology company's stock valued at $830,000 after acquiring an additional 43 shares during the period. Finally, Wealthspan Partners LLC grew its stake in shares of Axon Enterprise by 4.9% in the second quarter. Wealthspan Partners LLC now owns 965 shares of the biotechnology company's stock worth $284,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.
AXON has been the subject of a number of research reports. Robert W. Baird increased their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Northland Securities increased their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an "outperform" rating in a research note on Thursday, August 8th. Barclays boosted their price target on Axon Enterprise from $381.00 to $387.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Bank of America started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a "buy" rating and a $380.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $400.00 price objective on shares of Axon Enterprise in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of "Moderate Buy" and an average price target of $365.38.
Check Out Our Latest Report on Axon Enterprise
In related news, Director Matthew R. Mcbrady sold 2,000 shares of Axon Enterprise stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares of the company's stock, valued at $1,783,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Matthew R. Mcbrady sold 2,000 shares of the company's stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now directly owns 4,892 shares in the company, valued at approximately $1,783,916.72. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm's stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the sale, the director now directly owns 7,379 shares of the company's stock, valued at approximately $2,752,588.37. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 370,172 shares of company stock worth $136,562,182. Insiders own 6.10% of the company's stock.
NASDAQ:AXON opened at $421.80 on Monday. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The firm has a market cap of $31.83 billion, a PE ratio of 123.33, a price-to-earnings-growth ratio of 10.84 and a beta of 0.94. Axon Enterprise, Inc. has a 12 month low of $192.63 and a 12 month high of $422.33. The company's 50-day moving average price is $365.66 and its two-hundred day moving average price is $323.62.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise's revenue was up 34.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.80 EPS. On average, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.